7 stories mentioning BAX
Every FINWIRES story that references BAX, newest first.
Baxter International (BAX) has an average rating of hold and mean price target of $20.55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our price target to $19 from $23, using a forward P/E of 9.5x our 2027 EPS view, a sizable discount to BAX's 10-year historical forward average. We slightly adjust our 2026 EPS estimate to $2.00 from $1.96 and maintain our 2027 EPS estimate at $1.99. Baxter delivered mixed Q1 results that reflected ongoing operational challenges despite management's transformation efforts, in our view. Sales of $2.7 billion rose 3% on a reported basis but declined 1% organically. EPS was $0.36, a 35% Y/Y decrease from the prior year, reflecting significant headwinds from tariffs, higher manufacturing costs, and an unfavorable comparison with Q1 2025. We think that BAX could be in the early stages of a turnaround focused on stabilizing the business and strengthening the balance sheet. Yet, we see the potential for a slowdown in U.S. hospital capital spending due to macroeconomic uncertainties along with continued softer demand for inhaled anesthesia products globally as important risks.
Baxter International (BAX) has an average rating of Hold and mean price target of $20.55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $17.22, Change: $-0.36, Percent Change: -2.05%
Baxter International (BAX) has an average rating of Hold and mean price target of $20.55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $17.22, Change: $-0.36, Percent Change: -2.05%
Baxter International (BAX) has an average rating of Hold and mean price target of $20.55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $17.22, Change: $-0.36, Percent Change: -2.05%
Baxter International (BAX) has an average rating of Hold and mean price target of $20.55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $17.24, Change: $-0.34, Percent Change: -1.96%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Baxter delivered mixed Q1 2026 results with sales of $2.7B (+3% reported, -1% organic) beating consensus by $80M, though organic decline highlighted execution issues. Adjusted EPS of $0.36 beat expectations by $0.05 but declined 35% Y/Y due to unfavorable expense timing and higher manufacturing costs. We view the persistent operational challenges across key divisions as concerning despite management's transformation efforts. Management reiterated full-year 2026 guidance of flat to 1% sales growth and adjusted EPS of $1.85-$2.05, emphasizing progress on the Baxter Growth and Performance System with 230+ Q1 initiatives. Segment performance remained mixed with Medical Products & Therapies generating $1.3B (+2% reported, -2% organic) hampered by infusion pump issues, while Pharmaceuticals provided strength at $621M (+7% reported). We believe the ongoing execution challenges underscore the complexity in stabilizing operations despite improved free cash flow of $76M vs. -$221M in the prior year.